Key points from article :
resTORbio is targeting the aging immune system with an immune system-boosting drug.
Its primary candidate drug is RTB101, which targets part of the mTOR pathway.
Company announced positive results of its phase 2b human trial in 2018.
Reduced occurrence of respiratory tract infections (RTIs) which can lead to hospitalisation.
Has agreed two phase 3 clinical trials with FDA with nearly 3,000 participants.
Both trials will be randomized, double-blinded, and placebo-controlled.
